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Abstract
Background: The faecal reservoir provides optimal conditions for the transmission of resistance genes within and
between bacterial species. As key transmitters of infection within communities, children are likely important contributors
to endemic community resistance. We sought to determine the prevalence of antibiotic-resistant faecal Escherichia coli
from asymptomatic children aged between 0 and 17 years worldwide, and investigate the impact of routinely
prescribed primary care antibiotics to that resistance.
Methods: A systematic search of Medline, Embase, Cochrane and Web of Knowledge databases from 1940 to 2015.
Pooled resistance prevalence for common primary care antibiotics, stratified by study country OECD status. Random-
effects meta-analysis to explore the association between antibiotic exposure and resistance.
Results: Thirty-four studies were included. In OECD countries, the pooled resistance prevalence to tetracycline was 37.
7 % (95 % CI: 25.9–49.7 %); ampicillin 37.6 % (24.9–54.3 %); and trimethoprim 28.6 % (2.2–71.0 %). Resistance in non-
OECD countries was uniformly higher: tetracycline 80.0 % (59.7–95.3 %); ampicillin 67.2 % (45.8–84.9 %); and trimethoprim
81.3 % (40.4–100 %). We found evidence of an association between primary care prescribed antibiotics and resistance
lasting for up to 3 months post-prescribing (pooled OR: 1.65, 1.36–2.0).
Conclusions: Resistance to many primary care prescribed antibiotics is common among faecal E. coli carried by
asymptomatic children, with higher resistance rates in non-OECD countries. Despite tetracycline being contra-indicated
in children, tetracycline resistance rates were high suggesting children could be important recipients and transmitters
of resistant bacteria, or that use of other antibiotics is leading to tetracycline resistance via inter-bacteria resistance
transmission.
Background
The global emergence of antibiotic resistant bacterial in-
fections is arguably the greatest 21st century threat to
human health. The reasons for its emergence are com-
plex and likely to include interactions between: the way
in which antibiotics are used, particularly in primary
care, where 80 % of all health service antibiotics are
prescribed [1]; patient misuse through suboptimal dosing
and antibiotic storage for future symptoms; over-the-
counter (OTC) use; and community contacts and trans-
mission. The more antibiotics a population is exposed to,
the easier it becomes for resistant bacteria to spread and
persist within communities. As key transmitters of infec-
tion within communities [2], children are likely to be im-
portant contributors to endemic community resistance.
The faecal reservoir provides optimal conditions for
the transmission of resistance genes within and between
bacterial species. E. coli is among the most abundant
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organisms in the faecal flora, both in humans and ani-
mals. E. coli is an opportunistic pathogen, and a com-
mon cause of urinary tract, bloodstream, and foodborne
infections, and a cause of meningitis in neonates [3].
Whilst antibiotic use is likely to be the main driver of se-
lection pressure contributing to antibiotic resistance [4],
previous research has also demonstrated that intestinal
bacteria can acquire resistance to certain antibiotics in
the absence of antibiotic exposure [5]. How this resist-
ance is acquired is unclear, but could be as a result of
person-to-person transmission or environmental acquisi-
tion of resistant bacteria.
There has been little research published exploring fae-
cal carriage of bacterial resistance in any asymptomatic
population. This could provide important information
regarding carriage and transmission of resistant bacteria
within and between populations. This is particularly im-
portant in low-income countries, where antibiotics are
often available OTC, without the need for a prescription
[6]. Misuse of antibiotics in this way can expose harmless
or opportunistic bacteria to a plethora of antibiotics to
which they develop resistance. We conducted a systematic
review aimed to investigate the carriage of faecal E. coli
from asymptomatic children resistant to commonly pre-
scribed primary care antibiotics, and quantify the relation-
ship between previous exposure to primary care antibiotics
and bacterial resistance. We stratified data by study coun-
try Organisation for Economic Co-operation and Develop-
ment (OECD) status, as antibiotics can often be used
differently in these population groups; antibiotics are ob-
tained mostly by prescription only in OECD countries,
whereas in non-OECD countries many antibiotics can be
obtained over-the-counter [7–11].
Methods
Search strategy and selection criteria
We searched Medline, Embase, Cochrane and ISI Web
of Knowledge databases for articles published in any lan-
guage between 1940 and September 2015. MeSH terms
for these databases included “drug resistance”, “faeces”,
“carrier state” and “children”. MeSH terms were com-
bined with text word searches which included “antibiotics”,
“resistance”, “faecal/fecal”, “colonisation”, “commensal” and
“paediatric/pediatric”. Grey and unpublished literature was
searched for using ISI Web of Knowledge software and in-
cluded journal articles, websites, conference proceedings,
government and national reports and open access material.
Reference lists of selected key papers were screened
and authors who appeared multiple times in our search
were contacted to request details of further published and
unpublished work. All full-text papers were subject to cit-
ation searches. See Additional file 1 for full search strategy.
The review protocol is available on PROSPERO
(http://www.crd.york.ac.uk/PROSPERO/), registration
number CRD42014009691.
Two independent reviewers screened all titles and ab-
stracts for eligibility. Studies were eligible if they met the
following criteria: investigated and reported carriage of
resistance in faecal E. coli from asymptomatic children,
that is children who were not showing symptoms of in-
fection at the time the sample was taken; or investigated
associations between previous antibiotic exposure and
carriage of resistant E. coli; and study participants were
children aged 0–17 years, including healthy neonates
with an uncomplicated vaginal birth.
Data extraction and quality assessment
Full-text papers for all eligible studies were obtained and
three reviewers extracted data independently using a
purpose-built spreadsheet. The following information
was extracted from each paper, where provided: author,
journal, year of publication, study design, study country,
economic status, participants and recruitment location,
recruitment time period, age range, method of faecal
sample collection and testing, method of antimicrobial
sensitivity testing, bacteria cultured and reported anti-
biotic sensitivities, previously prescribed antibiotics and
time between antibiotic exposure and faecal sample col-
lection. Economic status was measured using the OECD
status of the country where the study was conducted [12].
The OECD is an international economic organisation first
established in 1948, now made up of 34 countries, which
aims to work together and with emerging and developing
economies to reduce poverty through economic growth
and financial stability [12]. OECD member countries tend
to be ‘developed’ countries, whereas non-OECD countries
tend to be ‘developing’. For the purpose of this review, we
use OECD status as a general measure of country-level
development, and a proxy marker for OTC antibiotic use.
For antimicrobial exposure, time was generally recorded
as a period of days, weeks or months prior to the faecal
sample being taken and resistance being measured when
the child had been exposed to any, or specific named anti-
biotics. Where any information was unclear in the paper,
authors were contacted for clarification.
We reported resistance to antibiotics commonly pre-
scribed to children in primary care, including for urinary
tract infection or other indications including respiratory
and skin infections. Resistance data was extracted and
reported for the following antibiotics: ampicillin, co-
amoxiclav (amoxicillin-clavulanic acid), co-trimoxazole
(trimethoprim-sulfamethoxazole), trimethoprim, nitro-
furantoin, ciprofloxacin, ceftazidime, tetracycline and
chloramphenicol. Ceftazidime was the most frequently
reported of all first to third generation cephalosporins,
and acts as a marker for cephalosporin resistance.
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Included papers were assessed for quality using a check-
list based on Cochrane collaboration’s ‘risk of bias’ tool
[13], We focused our quality criteria on factors we consid-
ered important for the review, namely: a reliable measure
of antibiotic exposure and resistance, clear reporting of
bacterial resistance, and clear reporting of children as
asymptomatic or non-infected. For papers which included
information on previous antibiotic exposure, we supple-
mented these with assessment of reporting adjustment for
confounders including age, sex and socioeconomic status.
Data synthesis and analysis
All statistical analyses were conducted using STATA ver-
sion 13 software, and all methods undertaken according
to PRISMA guidelines [14].
We calculated pooled prevalence of resistance estimates
by generating a Forest plot for each antibiotic, stratified by
OECD status. Forest plots illustrated proportion of resistant
E. coli for each country, along with 95 % confidence inter-
vals (CI), and the pooled prevalence of resistance per anti-
biotic per economic country group (OECD vs. non-OECD).
We calculated pooled estimates for each country and for
OECD and non-OECD groups using the pooled country es-
timates. Pooled prevalence estimates were generated for
children of all age groups (0–90 days, 0–5 years and 5–
17 years) and for defined time periods (1970–1979, 1980–
1989, 1990–1999, 2000–2010, 2010–2015), for comparison.
An I2 of 25, 50 and 75 % were used to signify low-level,
moderate-level and high-level heterogeneity, in line with
Cochrane recommendations [13]. All pooled estimates and
95 % confidence intervals (CI) were generated using double
arcsine transformation to adjust for variance instability.
This avoids implausible 95 % CI for prevalence estimates
when generated under the normal approximation [15].
For studies investigating the association between previous
antibiotic exposure and bacterial resistance, the outcome
measure was the odds ratio (OR) of bacterial resistance in
children previously exposed to any antibiotic compared to
those children who were previously unexposed. The crude
estimates from these studies were grouped according to the
reported preceding exposure time period (0–2 weeks, 0–
1 month and 0–3 months). A random-effects meta-analysis
was conducted where heterogeneity was moderate-to-high
and a pooled OR was generated for each exposure time
period measured. These were compared to adjusted OR for
each time period, where reported. Variables which were
adjusted for were family member antibiotic exposure,
previous hospitalisation, day care attendance, nappy use,
ethnicity and socio-economic status (see Additional file 2).
We assessed heterogeneity using the I2 statistic, and the
null hypothesis of no heterogeneity was tested using the Q
statistic generated from the χ2 test. Finally, funnel plots
were generated to explore the possibility of small study ef-
fects, which can be caused by publication bias.
Results
Study characteristics
We initially identified 12,997 potentially eligible articles.
Of these, 8995 non-duplicate papers were assessed and
8697 excluded on basis of title (Fig. 1). The remaining 298
papers were assessed by abstract screening of which 240
were excluded. For the remaining 58, full-text papers were
assessed, with 24 papers excluded. Thirty-four papers
were therefore included in the review [16–49], of which
six papers reported previous antibiotic exposure data and
were included in our meta-analysis [19, 27, 33, 34, 37, 49].
Table 1 summarises the characteristics of the 34 stud-
ies. Additional study characteristics can be found in
Additional file 2. Twenty studies, reporting the resist-
ance status of 3864 E. coli isolates were conducted in
OECD countries (Fig. 2), and all were observational.
Fourteen studies, reporting the resistance status of 6699
isolates were conducted in non-OECD studies (Fig. 2),
and again, all were observational. Twenty-three studies
(14 OECD vs. 9 non-OECD) reported stool sampling as
the primary collection method, with 10 reporting rectal
swabs, and one study accepting both methods of collec-
tion. Antimicrobial sensitivity testing was carried out
using standard disk diffusion methods for all studies,
which were interpreted and reported according to either
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [50], or the Clinical and Laboratory
Standards Institute (CLSI) [51]. All study participants
were healthy, without symptoms of infection and re-
cruited in the community, schools and day care centres,
or at a primary care facility conducting routine child
health surveillance check-ups. Three papers, OECD only,
included healthy neonates following uncomplicated vagi-
nal delivery recruited from maternity units.
The quality assessment ‘traffic-light’ charts for the in-
cluded studies show that, for the six studies reporting anti-
biotic exposure information, reporting was generally good
for our all our key quality indicators (Additional file 3).
For studies reporting prevalence of resistance only, overall
quality was good with the exception of controlling for con-
founding and accurate reporting of methods of analysis.
Prevalence of resistance in faecal E. coli from
asymptomatic children
Figure 2 details the number of studies per country and
shows the global variation in resistance to ampicillin by
OECD status. Resistance to ampicillin in faecal E. coli from
asymptomatic children was highest in Mexico (OECD)
and Bolivia (non-OECD), with a pooled prevalence of 90
and 95 %, respectively. Ampicillin resistance was lowest in
Sweden (OECD), with a pooled prevalence of 12 %.
Table 2 shows the pooled prevalence of resistance to
antibiotics in faecal E. coli isolates and were obtained
from Forest plots generated for each antibiotic, which
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can be found in Additional files 4, 5, 6, 7, 8, 9, 10, 11
and 12.
In OECD countries, the highest pooled resistance preva-
lence was for tetracycline at 37.7 % (95 % CI: 25.9–
49.7 %), with ampicillin and trimethoprim resistance also
high at 37.6 and 28.6 %, respectively. Resistance to ceftazi-
dime was lowest in OECD countries at 0.3 % (0.1–0.8 %).
Similarly to OECD countries, in non-OECD countries
the highest pooled prevalence of resistance was observed
in the same antibiotics, with trimethoprim highest at
81.3 % (95 % CI: 40.4–100 %), followed by tetracycline
and ampicillin at 80.0 and 67.2 %, respectively.
Prevalence of resistance in different age groups
There were too few data to report pooled resistance
prevalence estimates for any given age group (0–90 days,
0–5 years, 5–17 years) for any antibiotic reported in this
review.
Prevalence of resistance across different time periods
Figure 3 shows a Forest plot of the pooled resistance
prevalence to ampicillin and tetracycline (for which data
were most complete), by OECD status, by decade. There
were too few data for all other antibiotics to report time
period estimates. For OECD countries, included studies
were conducted between 1970 and 2014, compared with
non-OECD countries which were conducted from 1990 to
2014. Once again, the graphs show the higher resistance
rates in non-OECD compared to OECD countries, how-
ever there is no evidence of a change in resistance over
time as the confidence intervals for each time period and
each antibiotic overlap.
Association between previous antibiotic exposure and
bacterial resistance
Figure 4 shows a Forest plot of six studies investigat-
ing the relationship between previous exposure to
antibiotics and resistance to a range of commonly
used primary care antibiotics. Within all antibiotic
exposure time periods, the crude odds of resistance
were generally greater for children exposed to antibi-
otics than those unexposed, though exposure at 0–
2 weeks was not found to be significantly associated
with resistance. The effect sizes are reasonably
Fig. 1 Data search and extraction (PRISMA flowchart)
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similar for all time periods, with the pooled OR of
resistance rising as the cumulative antibiotic expos-
ure period increases, though confidence intervals do
overlap between different time periods. Given the
overlap in exposure time periods, meta-regression
analysis was not appropriate.
Table 1 Study characteristics of included papers
Study Characteristics OECD (n = 20) Non-OECD (n = 14)
Number of papers Reference number Number of papers Reference number
Study Design:
Retrospective observational 12 [16–27] 10 [36–45]
Prospective observational 5 [28–32] 1 [46]
Cross-sectional 3 [33–35] 3 [47–49]
Number of study participants:
0–50 1 [21] 1 [38]
51–100 5 [25, 28, 30, 31, 34] 2 [42, 46]
101–200 7 [17, 18, 20, 22, 23, 29, 32] 2 [36, 40]
201–500 4 [24, 27, 33, 35] 2 [41, 43]
501–1000 3 [16, 19, 26] 5 [37, 39, 44, 47, 49]
1000+ 0 2 [45, 48]
Method of faecal sampling:
Stool sample 14 [17, 19–21, 23, 24, 27, 28, 30–35] 9 [36, 37, 39–41, 44, 46–48]
Rectal swab 5 [16, 18, 22, 25, 26] 5 [38, 42, 43, 45, 49]
Stool sample or rectal swab 1 [29] 0
Age range of childrena:
Neonates (0–90 days) 3 [30–32] 0
0–5 years 9 [18–21, 24, 28, 33–35] 7 [36, 37, 39, 41, 46, 48, 49]
5–17 years 4 [16, 23, 24, 26] 3 [40, 42, 44]
0–17 years 5 [17, 22, 25, 27, 29] 4 [38, 43, 45, 47]
Antibiotics reported:
Ampicillin 15 [16–19, 21, 22, 24–26, 29–32, 34, 35] 12 [36–45, 47]
Co-amoxiclav 5 [16, 17, 19, 21, 28] 2 [39, 47]
Co-trimoxazole 4 [16, 17, 19, 21] 10 [36–41, 43–45, 47]
Trimethoprim 7 [22, 26, 28, 29, 33–35] 2 [29, 42]
Nitrofurantoin 3 [26, 30, 35] 2 [43, 48]
Ciprofloxacin 4 [16, 17, 21, 27] 12 [37–43, 45–48]
Ceftazidime 4 [16–18, 21] 3 [36, 39, 47]
Tetracycline 13 [16, 17, 20, 21, 23–26, 29–32, 35] 10 [36–38, 40–45, 47]
Chloramphenicol 11 [16, 17, 21, 23, 25, 26, 29–32, 35] 10 [37–39, 41–45, 47, 48]
Previous exposure to antibioticsb:
0–2 weeks 2 [33, 34] 0
0–3 weeks 0 1 [37]
0–1 month 1 [19] 0
0–3 months 1 [27] 1 [49]
0–6 months 0 0
0–1 year 0 0
aAge 0–5 years: papers which report data specifically for this age group, 6–17 years: papers which report data specifically for this age group; 0–17 years: papers
which report data for the children within 0–17 years, and do not fit into the previous reported age groups. Papers may appear more than once depending on
how they have reported their results
bIndicates papers which reported information regarding previous exposure to antibiotics and the exposure time periods they investigated
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There was no evidence of within group heterogeneity
in the 0–3 month time period, with low heterogeneity in
the 0–2 week period and moderate heterogeneity in the
0–1 month periods. For those studies which reported
adjusted ORs, adjusting for family member antibiotic ex-
posure, previous hospitalisation, day care attendance,
nappy use, ethnicity and socio-economic status; we com-
pared these results with our crude estimates, though we
only had sufficient data to do this for exposure at 0–
3 months. The pooled adjusted (OR 1.70, 95 % CI: 1.36–
2.12) and crude (OR 1.65, 1.36–2.00) did not differ
substantially.
Publication bias
There were too few studies for any given exposure time
period to assess publication bias.
Discussion
Principal findings
In asymptomatic children, we found evidence of high rates
of faecal E. coli resistance to several commonly prescribed
primary care antibiotics, and we have shown that resist-
ance rates were consistently higher in non-OECD com-
pared to OECD countries. The routine use of primary
care antibiotics could be an important contributor to car-
riage of resistant E. coli which we showed persists at both
1 and 3 months post-antibiotic prescription.
Strengths and weaknesses
To our knowledge, this is the first systematic review and
meta-analysis to explore and report global evidence re-
garding faecal carriage of resistant bacteria in healthy,
community-resident children and associations with the
routine use of antibiotics in primary care. Our review was
rigorously conducted according to the Cochrane guide-
lines for Systematic Reviews [13]. We chose to stratify our
results by OECD status to reflect both national develop-
ment and likely OTC antibiotic availability [6, 52].
We are aware of four main limitations. First, antibi-
otics are used very differently within OECD and non-
OECD countries [53–56], and OTC antibiotic use is
difficult to measure. A systematic review conducted in
2011 reported high non-prescription antibiotic variabil-
ity across countries worldwide [52], and there is not
100 % agreement between OECD status and OTC anti-
biotic availability. However, we are not aware of a better
country-level alternative with respect to measuring global
prevalence of antibiotic resistance in relation to antibiotic
use, and none of the included studies reported or measured
OTC antibiotic availability. There was some variation in
heterogeneity for our pooled prevalence of resistance esti-
mates. Most heterogeneity was moderate at around 50 %,
higher heterogeneity was observed most frequently in our
estimates from non-OECD countries. This may be due to
the lack of information provided regarding the study popu-
lations; although all children were asymptomatic of infec-
tion, they may vary in other factors from country to
country, for example the comorbidities. Higher heterogen-
eity in non-OECD countries may also be a reflection of the
availability of certain antibiotics OTC in some countries.
We also acknowledge that factors other than antibiotic
usage and OTC availability can account for differences in
carriage of resistant bacteria between OECD and non-
OECD countries, including; poverty, poor sanitation, un-
stable governance, and lower levels of medicine regulation
[57]. Additionally, the majority of our non-OECD studies
Fig. 2 Geographical distribution of OECD and non-OECD countries, including number of included studies per countrya (OECD countries shown in
blue) [12]. Faecal carriage of E. coli resistant to ampicillin for each reporting country are shown in red. Authors own map. a One study was conducted
in the USA, but also reported resistance data from Venezuela and China, this study therefore appears three times [29]
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Table 2 Pooled prevalence (%) of resistance to antibiotics in faecal E. coli from asymptomatic children (see Additional files 4, 5, 6, 7, 8, 9, 10, 11 and 12 for corresponding Forest plots)
Antibiotics OECD Non-OECD
Pooled prevalence
(95 % CI)
Number of
isolates tested
Number of
studies
I2 Ref No. Pooled prevalence
(95 % CI)
Number of
isolates tested
Number of
studies
I2 Ref No.
Tetracycline 37.7 %
(25.9–49.7 %)
2438 13
(9 countries)
19.5 % [16, 17, 20, 21, 23–
26, 29–32, 35]
80.0 %
(59.7–95.3 %)
5401 10
(8 countries)
62.9 % [36–38, 40–45, 47]
Ampicillin 37.6 %
(24.9–54.3 %)
3053 15
(11 countries)
34.6 % [16–19, 21, 22, 24–
26, 29–32, 34, 35]
67.2 %
(45.8–84.9 %)
6139 12
(10 countries)
58.1 % [36–45, 47]
Trimethoprim 28.6 %
(2.2–71.0 %)
862 7
(4 countries)
47.2 % [22, 26, 28, 29, 33–35] 81.3 %
(40.4–100 %)
359 2
(3 countries)
50.3 % [29, 42]
Chloramphenicol 13.4 %
(5.2–24.0 %)
2224 11
(8 countries)
58.1 % [16, 17, 21, 23, 25,
26, 29–32, 35]
44.5 %
(24.1–66.6 %)
5665 10
(9 countries)
39.0 % [37–39, 41–45, 47, 48]
Co-trimoxazole 10.8 %
(5.7–16.7 %)
1007 4
(4 countries)
33.5 % [16, 17, 19, 21] 59.5 %
(31.3–85.7 %)
5439 10
(6 countries)
61.4 % [36–41, 43–45, 47]
Co-amoxiclav 7.2 %
(1.8–13.5 %)
1066 5
(5 countries)
37.9 % [16, 17, 19, 21, 28] 18.1 %
(14.7–21.6 %)
745 2
(2 countries)
8.8 % [39, 47]
Ciprofloxacin 5.1 %
(0.2–17.8 %)
586 4
(4 countries)
36.0 % [16, 17, 21, 27] 9.3 %
(3.4–17.2 %)
6231 12
(7 countries)
60.3 % [37–43, 45–48]
Nitrofurantoin 4.4 %
(0.6–9.3 %)
673 3
(3 countries)
54.4 % [26, 30, 35] 7.3 %
(5.9–9.7 %)
715 2
(2 countries)
0.0 % [43, 48]
Ceftazidime 0.3 %
(0.1–0.8 %)
177 4
(4 countries)
0.0 % [16–18, 21] 5.0 %
(0.7–15.6 %)
654 3
(3 countries)
28.8 % [36, 39, 47]
Ordered by pooled resistance prevalence in OECD countries (highest to lowest)
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were conducted in either South America or Asia, with
African countries under-represented in this group.
Second, reverse causality and other confounding associa-
tions including age, sex and previous hospitalisation, could
have introduced bias to our meta-analysis findings. How-
ever, analyses adjusting for confounding factors did not
demonstrate substantial differences between crude and ad-
justed association estimates. Third, our meta-analysis of
the association between antibiotic exposure and resistance
reported moderate heterogeneity within the 0–1 month
time period, however the difficulty in estimating a more
accurate point of antibiotic exposure may have accounted
for this. In addition to this, only six studies, conducted be-
tween 1987 and 2012 reported data on antibiotic exposure,
therefore these findings must be interpreted with caution,
but nevertheless provide some evidence to support the
possibility of an association between antibiotic exposure
and carriage of resistant bacteria. Finally, there were insuf-
ficient studies to adequately assess publication bias.
Results in the context of existing research
Carriage of resistant faecal E. coli in healthy children
Resistance to ampicillin in faecal E. coli isolates was high
for both OECD and non-OECD countries, particularly
Fig. 3 Pooled prevalence (%) of resistance to antibiotics in faecal E. coli from asymptomatic children across different time periods for ampicillin
(a and b) and tetracycline (c and d), split by OECD (a and c) and non-OECD (b and d) countries. Studies included more than once reported resistance
separately in different age groups or different geographic locations
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non-OECD countries which reached almost 65 %. There
is little data other than that which was included in this
review with which to compare estimates. However, the
highest reported resistance to ampicillin was very similar
to reported aminopenicillin group resistance in the
European Antimicrobial Resistance Surveillance Network
(EARS-Net) database and US Centre for Disease Dynam-
ics, Economics and Policy (CDDEP) databases [58, 59].
Given that such databases include clinical samples from
the general population, including older adults, the similar-
ities observed here could be a result of between age-group
transmission of genetic resistance factors such as plas-
mids; facilitated via frequent interaction between children
and adults. In addition, the EARS-Net and CDDEP data-
bases constitute ‘invasive’ clinical E. coli samples, taken
from blood or urine. This could suggest that the resistance
profiles of both commensal and pathogenic organisms are
similar. A recent systematic review exploring prevalence
of resistance to antibiotics in E. coli causing urinary tract
infection in children also reported similar estimates to fae-
cal E. coli [60], which further supports this theory.
Tetracycline can be used for a number of indications,
but is not recommended for use in children under 8 years
due to its association with permanent tooth discolouration
[61]. Despite this, the pooled resistance prevalence to
tetracycline was high in faecal E. coli from healthy children
in both OECD and non-OECD countries. Previous studies
in human faecal bacteria have reported that bacteria such
as E. coli which are resistant to tetracycline also tend to be
co-resistant to other antibiotics, including ampicillin and
sulphonamides [62]. A UK study reported that following
administration of amoxicillin in healthy adults, an increase
in tetracycline resistance genes was observed in E. coli fae-
cal isolates, an indication of co-selection of multiple anti-
biotic resistance genes [63]. The reason for the high-level
resistance to tetracycline in asymptomatic children may
not necessarily reflect exposure in individual children, but
exposure from their contacts; indicating that community-
level exposure to antibiotics may play a greater role in the
dissemination of resistant bacteria than individual expos-
ure in children. Additionally, there is considerable evi-
dence demonstrating the transfer of resistance genes
between animals and humans, whether through direct
contact with animals such as pets [64], or through the in-
gestion of animal food-products [65]. Whilst the use of an-
tibiotics, including tetracycline, as growth promoters in
food animals is no longer recommended in many
European countries, transfer of resistant bacteria in this
.
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Any antibiotic
Any antibiotic
Any antibiotic
Any antibiotic
Any antibiotic
exposure
Antibiotic
0.92 (0.50, 1.70)
1.94 (0.55, 6.91)
1.08 (0.60, 1.96)
1.34 (1.01, 1.78)
2.03 (1.52, 2.73)
1.49 (1.11, 2.00)
1.18 (0.86, 1.62)
1.44 (1.05, 1.99)
0.94 (0.51, 1.71)
1.38 (0.74, 2.55)
0.75 (0.33, 1.72)
0.28 (0.01, 5.88)
1.38 (1.16, 1.64)
1.53 (1.07, 2.19)
1.54 (1.08, 2.20)
1.71 (1.19, 2.45)
2.02 (1.24, 3.28)
1.65 (1.36, 2.00)
OR (95% CI)
1.01 .1 10 100
Fig. 4 Meta-analysis of individual studies examining association between previous primary care antibiotic exposure and carriage of bacterial resistance.
The Forest plot shows pooled crude and individual OR (log scale) for resistance in asymptomatic children’s faecal E. coli bacteria and previous exposure
to any antibiotic. Studies grouped according to time period during which exposure was measured and ordered within each time period by increasing
standard error
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manner continues to pose a global threat [66], as does vet-
erinary use of antibiotics, which is less well regulated than
human use.
Association between antibiotic exposure and carriage of
resistant E. coli
Our meta-analysis of the association between previous
exposure to antibiotics and bacterial resistance observed
associations which were stronger for longer time pe-
riods, namely 0–1 month and 0–3 months compared
with 0–2 weeks. There was no association found be-
tween antibiotic exposure within 0–2 weeks and carriage
of resistance; this may have been due to insufficient
sample size, or the fact that the studies measuring asso-
ciation within this time period were almost 30 years old,
whereas the studies measuring associations in other time
periods were more recent. Of the six studies included in
our meta-analysis, most reported the association be-
tween previous antibiotic exposure and resistance within
overlapping time periods. This implies that the associa-
tions with longer time periods (i.e. 0–3 months) could
reflect either long or short-term relationships. A previ-
ous systematic review demonstrated similar effects in
urinary and respiratory bacteria, in patients of all ages
[67]. That review found that the effect of antibiotic ex-
posure on the isolation of a resistant isolate may persist
for up to 12 months, something we were unable to ex-
plore because our review studies did not measure expos-
ure for this period.
Clinical, public health and research implications
Our findings demonstrate the high-level resistance to
some of the most commonly prescribed primary care an-
tibiotics in faecal isolates from healthy children, and sug-
gest that one cause of carrying bacterial resistant faecal
flora in healthy children could be previous exposure to
antibiotics. Despite our data being obtained from asymp-
tomatic children, the clinical and public health implica-
tions of these findings are significant. First, they provide
further empirical data to support the importance of anti-
microbial stewardship and good sanitation, and that the
more antibiotics are prescribed and used within commu-
nities, either in humans, food products or farm animals
and pets, the greater the selection pressure is for resist-
ance to develop and persist. Resistant bacteria can be
shed from humans and animals in faeces which can con-
taminate the environment, including water supplies. Sec-
ond, faecal bacteria have been shown to be the source of
auto-infection, in which safely carried bacteria invade
other body areas and become pathogenic, leading to
UTI, meningitis, septicaemia and pneumonia [3]. Auto-
infection of resistant bacteria could result in the ineffect-
iveness of first-line antibiotic treatments, and without
the development of any new antibiotics, this poses
hazardous limitations on our continued ability to treat.
For primary care clinicians, the best course of action is
to consider the impact of any antibiotic use on anti-
microbial resistance, and avoid their unnecessary use by
following local and national guidance wherever possible.
Future studies should identify the extent of faecal shed-
ding and modes of antibiotic-resistant bacteria transmis-
sion within and between communities of humans, animals
and the surrounding environments.
Conclusions
Resistance to many commonly used primary care antibi-
otics in faecal E. coli isolates from asymptomatic chil-
dren ranged from moderate to very high, with resistance
being higher in non-OECD countries. Routine antibiotic
use is likely to be an important contributor to resistance,
which may persist for up to 3 months post-antibiotic
treatment. Despite the fact that tetracycline is contra-
indicated in children, the high rates of tetracycline resist-
ance suggest healthy children could be important recipi-
ents and transmitters of resistant bacteria and, or, that
use of other antibiotics is leading to tetracycline resist-
ance via inter-bacteria resistance transmission.
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